Current treatments of the anxiety disorders in adults

Biological Psychiatry

Volumn 46, Issue 11, 1999, Pages 1579-1594

  Ballenger, James C ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adults; Anxiety disorders; Cognitive behavioral therapy; Pharmacotherapy; Treatments

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BROFAROMINE; BUSPIRONE; CHLORDIAZEPOXIDE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; DIAZEPAM; DOXEPIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LORAZEPAM; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; OXAZEPAM; PAROXETINE; PHENELZINE; PINDOLOL; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ADULT; ADULTHOOD; ANXIETY NEUROSIS; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COMPULSION; CONFERENCE PAPER; HUMAN; HYPERTENSION; MENTAL DISEASE; OBSESSION; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RECURRENCE RISK; SOCIAL PHOBIA; WITHDRAWAL SYNDROME;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; HUMANS;

EID: 0032751401     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(99)00220-6     Document Type: Conference Paper

References (176)

1. Acierno R., Hersen M., Van Hasselt V.B., Tiermont C., Meisser K.T. Review of the validation and dissemination of eye movement desensitization and reprocessing A scientific and ethical dilema . Clin Psychol Rev. 14:1994;287-299.
2. Avraham Y., Mikulineer M., Nardi C., Shaham S. The use of individual goal setting and ongoing evaluation in the treatment of combat-related chronic PTSD. J Trauma Stress. 5:1992;195-204.
3. Ballenger J.C. Medication discontinuation in panic disorder. J Clin Psyciatry. 53S:1992;26-31.
4. Ballenger J.C. Benzodiazepines. Schatzberg A.F., Nemeroff C.B. The American Psychiatric Press Textbook of Psychopharmacology. 1995;215-230 American Psychiatric Press, Inc, Washington, DC.
5. Ballenger J.C. Selective serotonin reuptake inhibitors (SSRIs) in panic disorder. Nutt D., Ballenger J.C., Lepine J. Panic Disorder Clinical Diagnosis and Management . 1999;159-178 Martin, Dunitz Ltd, London.
6. Ballenger J.C., Davidson J.R., Lecrubier Y., Nutt D.J., Baldwin D.S., den Boer J.A. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 59:(suppl 8):1998;47-54.
7. Ballenger J.C., Davidson J.R., Lecrubier Y., Nutt D.J., Bobes J., Beidel D.C., Ono Y., Westenberg H.G. Consensus statement on social anxiety disorder from the international consensus group on depression and anxiety. J Clin Psychiatry. 59:(suppl 17):1998;54-60.
8. nd edition) :1997;1421-1452 American Psychiatric Press, Washington, DC.
9. Ballenger J.C., Steiner M., Bushnell W., Gergel I. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 155:1998;36-42.
10. Baer L., Rauch S.L., Ballantine T. Jr, Martuza R., Cosgrove R., Cassem E., et al. Cingulotomy for intractable obsessive-compulsive disorder. Arch Gen Psychiatry. 52:1995;384-392.
11. Barlow D.H. Behavioral conception and treatment of panic. Psychopharm Bull. 22:1986;802-806.
12. Barlow D.H. Anxiety and Its Disorders The Nature and Treatment of Anxiety and Panic . 1988;Guilford, New York.
13. Barlow D.H., Craske M.G., Cerny J.A., Klosko J.S. Behavioral treatment of panic disorder. Behav Ther. 20:1989;261-282.
14. Barlow D.H., Cohen A.S., Waddell M., Vermilyea J.A., Klosko J.S., Blanchard E.B., DiNardo P.A. Panic and generalized anxiety disorders Nature and treatment . Behav Ther. 15:1984;431-449.
15. Barlow D.H., Lehman C. Advances in the psychosocial treatment of anxiety disorders Implications for national health care . Arch Gen Psychiatry. 53:1996;727-735.
16. Barlow D, Shear K, Woods S, Gorman JA (1998, March): A multicenter trial comparing cognitive behavior therapy, imipramine, their combination and placebo. Presented at the annual convention of the Anxiety Disorders Association of America, Boston, MA.
17. Beale M.D., Kellner C.H., Pritchett J.T., Burns C.M. ECT for OCD. J Clin Psychiatry. 56:1995;81.
18. Behar D., Winokur G., Van Valkenburg C., Lowry M. Familial subtypes of depression A clinical view . J Clin Psychiatry. 41:1980;52-56.
19. Bisserbe J.C., Lepine J.P., Le-Goubey P., Rigaud P., Albert E., Chneweiss L., et al. Moclobemide in social phobia A pilot open study . Clin Neuropharmacol. 17:(suppl 3):1994;88-94.
20. Blake D.D. Treatment outcome research on PTSD. Clin Psychol Clin Newsletter. 3:1993;14-17.
21. Bleich A., Siegel B., Garb R., Lerer B. Post-traumatic stress disorder following combat exposure Clinical features and psychopharmacological treatment . Br J Psychiatry. 149:1986;365-369.
22. Borkovec T.D., Costello E. Efficacy of applied relaxation and cognitive-behavioral therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol. 61:1993;611-619.
23. Borkovec T.D., Mathews A.M. Treatment of nonphobic anxiety disorders A comparison of nondirective, cognitive, and coping desensitization therapy . J Consult Clin Psychol. 56:1988;877-884.
24. Boudewyns P.A., Hyer L. Eye movement desensitization and reprocessing (EMDR) as treatment for post-traumatic stress disorder (PTSD). Clin Psychol Psychother. 3:1996;185-195.
25. Bowden C.L., Fisher J.G. Safety and efficacy of long-term diazepam therapy. South Med J. 73:1980;1581-1584.
26. Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks A meta-analysis . Int Clin Psychopharmacol. 10:1995;45-49.
27. Brown T., Barlow D. Long-term outcome in cognitive behavioral treatment of panic disorder Clinical predictors and alternative strategies for assessment . J Consult Clin Psychol. 63:1995;754-765.
28. Busto V., Simpkins J., Sellers E.M., Sisson B., Segal R. Objective determinations of benzodiazepine use and abuse in alcoholics. Br J Addict. 78:1983;429-435.
29. Butler G., Fennell M., Robson P., Gelder M. Comparison of behavior therapy in the treatment of generalized anxiety disorder. J Consult Clin Psychol. 59:1991;167-175.
30. Chambless D.L., Gillis M.M. Cognitive therapy of anxiety disorders. J Consult Clin Psychol. 61:1993;248-260.
31. Ciraulo D.A., Barnhill J.G., Greenblatt D.J., Shader R.I., Ciraulo A.M., Tarmey M.F., et al. Abuse liability and clinical pharmacokinetics of alprazolam in alcoholic men. J Clin Psychiatry. 49:1988;333-337.
32. Clark D.M. A cognitive approach to panic. Behav Res Ther. 24:1986;461-470.
33. Clark D.M., Salkovskis P.M., Hackmann A., Middleton H., Anastasiades P., Gelder M. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry. 164:1994;759-769.
34. Clomipramine in the treatment of obsessive compulsive disorder. Arch Gen Psychiatry. 48:1991;730-737.
35. Clum G.A., Clum G.A., Surls R. A meta-analysis of treatments for panic disorder. J Consul Clin Psychol. 61:1993;317-326.
36. Cox B., J Endler N.S., Lee P.S., Swinson R.P. A meta-analysis of treatments of panic disorder with agoraphobia Imipramine, alprazolam, and in vivo exposure . J Behav Ther Exp Psychiatry. 23:1992;175-182.
37. Craske M.G., Brown T.A., Barlow D.H. Behavioral treatment of panic disorder A two-year follow-up . Behav Ther. 22:1991;289-304.
38. Drug treatment of panic disorder comparative efficacy of alprazolam, imipramine and placebo . Br J Psychiatry. 160:1993;191-202.
39. Davidson J.R.T. Drug therapy of post-traumatic stress disorder. Br J Psychiatry. 160:1992;309-314.
40. Davidson J.R.T., Hughes D., Blazer D.G., George L.K. Post-traumatic stress disorder in the community An epidemiological study . Psychol Med. 21:1991;713-721.
41. Davidson J.R.T., Kudler H.S., Saunders W.B., Erickson L., Smith R.D., Stein R.M., et al. Predicting response to amitriptyline in post-traumatic stress disorder. Am J Psychiatry. 150:1993;1024-1029.
42. Davidson J.R.T., Malik M.L., Sutherland S.N. Response characteristics to antidepressants and placebo in post-traumatic stress disorder. Review. Int Clin Psychopharm. 12:(6):1997;291-296.
43. Davidson J.R., Potts N., Richichi E., Krishnan R., Ford S.M., Smith R. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharm. 13:(6):1993;423-428.
44. Davidson J.R.T., Weisler R.H., Malik M.L., Connor K.M. Treatment of posttraumatic stress disorder with nefazodone. Inter Clin Psychopharmacol. 13:1998;111-113.
45. DeMartinis N.A., Schweizer E., Rickels K. An open-label trial of nefazodone in high comorbidity panic disorder. J Clin Psychiatry. 57:1996;245-248.
46. Den Boer J.A. Pharmacotherapy of panic disorder Differential efficacy from a clinical viewpoint . J Clin Psychiatry. 59:(suppl 8):1998;30-36.
47. Derivan A, Entsuah R, Haskins JT, Rudolph R (1997, December): Double-blind, placebo-comparator-controlled study of once daily venlafaxine XR and buspirone in outpatients with Generalized Anxiety (GAD). Presented at the meeting of the American College of Neuropsychopharmacology, Honolulu.
48. Fahlen T., Nilsson H.L., Borg K., Humble M., Pauli U. Social phobia The clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study . Acta Psych Scandina. 92:1995;351-358.
49. Fals-Stewart W., Marks A.P., Schafer J. A comparison of behavioral group therapy and individual behavior therapy in treating obsessive-compulsive disorder. J Nerv Ment Dis. 181:1993;189-193.
50. Foa E.B. Trauma and women course, predicators, and treatment . J Clin Psychiatry. 58:(suppl 9):1997;25-28.
51. Foa E.B., Rothbaum B.O., Riggs D.S., Murdock T.B. Treatment of posttraumatic stress disorder in rape victims A comparison between cognitive-behavioral procedures and counseling . J Consul Clin Psychology. 59:1991;715-723.
52. Foa E.B., Steketee G.S., Ozarow B.J. Behavior therapy with obsessive-compulsives from theory to treatment . Mavissakalian M., Turner S.M., Michelson L. Obsessive-Compulsive Disorder Psychological and Pharmacological Treatment . 1985;49-129 Plenum Press, New York.
53. Frank J.B., Kosten T.R., Giller E.L., Dan E. A randomized clinical trial of phenelzine and imipramine for post-traumatic stress disorder. Am J Psychiatry. 145:1988;1289-1291.
54. Frueh C.B., Turner S.M., Beidel D.C. Exposure therapy for combat-related PTSD A critical review . Clin Psychol Rev. 15:1995;799-817.
55. Gelernter C.S., Uhde T.W., Cimbolic P., Arnkoff D.B., Vittone B.J., Tancer M.E., et al. Cognitive-behavioral and pharmacological treatments for social phobia A controlled study . Arch Gen Psych. 48:1991;938-945.
56. Goodman W.K., Price L.H., Rasmussen S.A., Delgado P.L., Heninger G.R., Charney D.S. Efficacy of haolperidol addition in fluvoxamine in obsessive-compulsive disorder A double-blind comparison with placebo . Arch Gen Psych. 46:1989;36-44.
57. Greenblatt D.J., Shader R.I. Drug therapy. Benzodiazepines, (first of two parts). New Engl J Med. 291:1974;1011-1015.
58. Greenblatt D.J., Shader R.I. Drug therapy. Benzodiazepines (second of two parts). New Engl J Med. 291:1974;1239-1243.
59. Greenblatt D.J., Shader R.I., Abernethy D.R. Drug Therapy Current status of benzodiazepines. Part One . N Engl J Med. 309:1983;354-358.
60. Greenblatt D.J., Shader R.I., Abernethy D.R. Drug Therapy Current status of benzodiazepines. Part Two . N Engl J Med. 309:1983;410-416.
61. Greist J.H. Behavior therapy for obsessive compulsive disorder. Review. J Clin Psychiatry. 55:(suppl):1994;60-68.
62. Greist J, Chouinard G, DuBoff E, Lararis A, Kim S, Koran L, et al (1992 month): Double-blind comparison of three doses of sertraline in obsessive-compulsive disorder. Presented at the 28th meeting of the College of International Neuropsychopharmacology Congress. Nice, France.
63. Greist J.H., Jefferson J.W., Kobak K.A., Katzelnick D.J., Serlin R.C. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder A meta-analysis . Arch Gen Psychiatry. 52:1995;53-60.
64. Hammarberg M., Silver S.M. Outcome of treatment for post-traumatic stress disorder in a primary care unit serving Vietnam veterans. J Trau Stress. 7:1994;195-216.
65. Hand I. Ambulante Verhaltenstherapie bei Zwangsstorungen. Fortschr Neurol Psychia. 63:(1):1995;12-18.
66. Haskins JT, Aguiar L, Pallay A, Rudolph R (1999a, March). Double-blind, placebo-controlled study of once daily venlafaxine XR (V-XR) in outpatients with Generalized Anxiety Disorder. Presented at the annual meeting, Anxiety Disorders Association of America, San Diego, CA.
67. Haskins JT, Rudolph R, Aguiar L, Entsuah R (1998, October-November). Double-blind, placebo-comparator-controlled study of once daily venlafaxine XR (V-XR) and buspirone (Bsp) in outpatients with Generalized Anxiety Disorder (GAD). Presented at the meeting of the European College of Neuropsychopharmacology, Paris.
68. Haskins JT, Rudolph R, Aguiar L, Entsuah R (1999b, March). Double-blind, placebo-/comparator-controlled study of once daily venlafaxine XR (V-XR) and buspirone (Bsp) in outpatients with Generalized Anxiety Disorder (GAD). Presented at the annual meeting of the Anxiety Disorders Association of America, San Diego.
69. Hedges D.W., Reimherr F.W., Strong R.E., Halls C.H., Rust C. An open trial of nefazodone in adult patients with generalized anxiety disorder. Psychopharm Bull. 32:1996;671-676.
70. Hegel M.T., Ravaris C.L., Ahles T.A. Combined cognitive-behavioral and time-limited alprazolam treatment of panic disorder. Behav Ther. 25:1994;183-195.
71. Heimberg R.G., Liebowitz M.R., Hope D.A., Schneier F.R., Holt C.S., Welkowitz L.A., et al. Cognitive behavioral group therapy vs. phenelzine therapy for social phobia 12-week outcome . Arch Gen Psych. 55:1998;1133-1141.
72. Heimberg R.G., Salzman D.G., Holt C.S., Blendell K.A. Cognitive behavioral group treatment for social phobia Effectiveness at five-year follow-up . Cog Ther Res. 17:1993;325-339.
73. Hertzberg M.A., Feldman M.E., Beckham J.C., Moore S.D., Davidson J.R.T. Open trial of nefazodone for combat-related posttraumatic stress disorder. J Clin Psychiatry. 59:1998;460-464.
74. Hickling E.J., Blanchard E.B. The private practice psychologist and manual-based treatments Post-traumatic stress disorder secondary to motor vehicle accidents . Behav Res Ther. 35:1997;191-203.
75. Hiss H., Foa E.B., Kozak M.J. Relapse prevention program for treatment of obsessive-compulsive disorder. J Consult Clin Psychol. 62:1994;801-808.
76. Hoehn-Saric R, McLeod DR, Zimmerli WD (1988): Differential effects of alprazolam and imipramine in generalized anxiety disorder: Somatic versus psychic symptoms. J Clin Psychiatry 49:669-667.
77. Hollister L.E., Conley F.K., Britt R.H., Shuer L. Long-term use of diazepam. JAMA. 246:1981;1568-1570.
78. Horowitz M. Stress response syndromes, character style, and dynamic psychotherapy. Arch Gen Psychiatry. 31:1974;768-781.
79. Johnstone E.C., Cunningham-Owens D.G., Frith C.D., McPherson K., Dowie C., Riley G., et al. Neurotic illness and its response to anxiolytic and anti-depressant treatment. Psychol Med. 10:1980;321-328.
80. Jaffe J.H., Ciraulo D.A., Nies A., Dixon R.B., Monroe L.L. Abuse potential of halazepam and of diazepam in patients recently treated for acute alcohol withdrawl. Clin Pharmacol Ther. 34:1983;623-630.
81. Jefferson W.J. Antidepressants in panic disorder. J Clin Psychiatry. 58:(suppl 2):1997;20-24.
82. Jenike M.A., Rauch S.L. Managing the patient with treatment-resistant obsessive compulsive disorder Current strategies . J Clin Psychiatry. 55:(suppl. 3):1994;11-17.
83. Jobson K.O., Davidson J.R., Lydiard R.B., McCann U.D., Pollack M.H., Rosembaum J.F. Algorithm for the treatment of panic disorder with agoraphobia. Psychopharmacol Bull. 31:1995;483-485.
84. Johnson D.R., Feldman S.C., Southwick S.M., Charney D.S. The concept of the Second Generation program in the treatment of post-traumatic stress disorder among Vietnam veterans. J Trau Stress. 7:1994;217-235.
85. Judge R., Steiner M. The long-term efficacy and safety of paroxetine in panic disorder. Eur Neuropsychopharmacol. 6:(suppl 3):1996;207. (abstract).
86. Juster H.R., Heimberg R.G. Social Phobia Longitudinal course and long-term outcome of cognitive-behavioral treatment. Review . Psychiatr Clin North Am. 18:1995;821-824.
87. Kahn R.J., McNair D.M., Covi L. Effects of psychotropic agents on high anxiety subjects. Psychopharmacol Bull. 17:1981;97-103.
88. Kahn R.J., McNair D.M., Lipman R.S., Covi L., Rickels K., Downing R., et al. Imipramine and chlordiazepoxide in depressive and anxiety disorders. II. Efficacy in anxious out-patients. Arch Gen Psychiatry. 43:1986;79-85.
89. Kastenholz K.V. Buspirone, a novel nonbenzodiazepine anxiolytic. Clin Pharmacol. 3:1984;600-607.
90. Katschnig H., Amering M.A., Stolk J.M., Klerman G.L., Ballenger J.C., Briggs A., et al. Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry. 167:1995;487-494.
91. Katschnig H., Stein M., Buller R. Moclobemide in social phobia A double-blind, placebo-controlled clinical study . Eur Arch Psychiatry Clin Neurosci. 247:1997;71-80.
92. Katzelnick D.J., Kobak K.A., Greist J.H., Jefferson J.W., Mantle J.M., Serlin R.C. Sertraline for social phobia A double-blind, placebo-controlled, crossover study . Am J Psychiatry. 152:1995;1368-1371.
93. Keck P.E. Jr, McLeroy S.L., Friedman L.M. Valoprate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. Review. J Clin Psychopharm. 12:(suppl 1):1992;36S-41S.
94. Kelsey J.E. Venlafaxine in social phobia. Psychopharmacol Bull. 31:1995;767-771.
95. Kilpatrick D.G., Veronen L.J., Resnick P.A. Psychological sequelae to rape. Dojeys D.M., Meredith R.L., Ciminero A.R. Behavioral Medicine Assesment and Treatment Strategies . 1982;473-496 Plenum Publishing Corporation, New York.
96. Kobak K.A., Greist J.H., Jefferson J.W., Katzelnick D.J., Henk H.J. Behavioral versus pharmacological treatments of obsessive compulsive disorder A meta-analysis . Psychopharmacol. 136:1997;205-216.
97. Laird L.K., Benefield W.H. Mood disorders I Major depressive disorders . Young L.Y., Koda-Kimble M.A. Applied Theraputics The Clinical Use of Drugs 6th ed . 1995;1-76 Applied Therapeutics, Vancouver, WA.
98. Lecrubier Y., Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psych Scand. 95:(2):1997;153-160.
99. Lesser I.M., Rubin R.T., Rifkin A., Swinson R.P., Ballenger J.C., Burrows G.D., et al. Secondary depression in panic disorder and agoraphobia. Dimensions of depressive symptomatology and their response to treatment. J Affective Dis. 16:1989;49-58.
100. Liebowitz M.R., Fyer A.J., Gorman J.M., Campeas R.B. Tricyclic therapy of DSM-III anxiety disorders A review with implications for further research . J Psychiatr Res. 22:(suppl 1):1988;7-31.
101. Liebowitz M.R., Schneier F., Campeas R., Hollander E. Phenelzine vs. atenolol in social phobia A placebo-controlled comparison . Arch Gen Psych. 49:1992;290-300.
102. Maletzky B., McFarland B., Burt A. Refractory obsessive compulsive disorder and ECT. Compulsive Ther. 10:1994;34-42.
103. Marchesi C., Ampollini P., Signifredi R., Maggini C. The treatment of panic disorder in a clinical setting A 12-month naturalistic study . Neuropsychobiology. 36:1997;25-31.
104. Margraf J., Barlow D.H., Clark D.M., Telch M.J. Psychological treatment of panic Work in progress on outcome, active ingredients, and follow-up . Behav Res Ther. 31:1993;1-8.
105. Marks I.M. Are there anticompulsive or antiphobic drugs? Review of the evidence. Br J Psych. 143:1983;338-347.
106. Marks I.M. Advances in behavioral-cognitive therapy of social phobia. J Clin Psychiatry. 56:(suppl 5):1995;25-31.
107. Marks I.M., Baer L., Greist J.H., Park J., Bachofen M., Nakagawa A., et al. Home self-assessment of obsessive-compulsive disorder Use of a manual and a computer-conducted telephone interview: Two UK-US studies . Br J Psychiatry. 172:1998;406-412.
108. Marks T.M., Matthews A.M. Brief standard self-rating for phobic patients. Behav Res Ther. 17:1979;263-267.
109. Martinsen E.W., Olsen T., Tonset E., Nyland K.E., Aarre T.F. Cognitive-behavioral group therapy for panic disorder in the general clinical setting A naturalistic study with 1-year follow-up . J Clin Psychiatry. 59:1998;437-442.
110. Mattick R.P., Andrews G., Hadzi-Pavlovic D., Christensen H. Treatment of panic and agoraphobia An integrative review . J Nerv Ment Disord. 178:1990;567-576.
111. Mattick R.P., Peters L. Treatment of severe social phobia Effects of guided exposure with and without cognitive restructuring . J Consult Clin Psychol. 56:1988;251-260.
112. Mavissakalian M., Michelson L. Agoraphobia Relative and combined effectiveness of therapist-assisted in vivo exposure and imipramine . J Clin Psychiatry. 47:1986;117-122.
113. Mavissakalian M.R., Perel J.M. Clinical experiments in maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry. 49:1992;318-323.
114. McDougle C.J., Goodman W.K., Leckman J.F., Lee N.C., Heninger G.R., Price L.H. Haloperidol addition in fluvoxamine-refractory obsessive compulsive disorder. Arch Gen Psychiatry. 51:1994;302-308.
115. McDougle C.J., Southwick S.M., Charney D.S., St. James R.L. An open trial of fluoxetine in the treatment of post-traumatic stress disorder. J Clin Psychopharmacol. 11:1991;325-327.
116. Mellinger G.D., Balter M.B., Uhlenhuth E.H. Prevalence and correlates of the long-term regular use of anxiolytics. JAMA. 251:1984;375-379.
117. Mersch P.P.A. The treatment of social phobia The differential effectiveness of exposure in vivo and an intergration of exposure in vivo, rational emotive therapy and social skills training . Behav Res Ther. 33:1995;259-269.
118. Michelson D., Lydiard R.B., Pollack M.H., Tamura R.N., Hoog S.L., Tepner R., et al. Outcome Assessment and clinical improvement in panic disorder Evidence from a randomized controlled trial of fluoxetine and placebo . Am J Psychiatry. 155:1998;1570-1577.
119. Milrod B., Busch F., Cooper A., Shapiro T. Manual of Panic-Focused Psychodynamic Psychotherapy. 1997;American Psychiatric Press, Washington, DC.
120. Mundo E., Bianchi L., Bellodi L. Efficacy of fluvoxamine, paroxetine, and citalopram in the treatment of obsessive-compulsive disorder A single-blind study . J Clin Psychopharmacol. 17:1997;267-271.
121. Munjack D.J., Bruns J., Baltazar P.L., Brown R., Leonard M., Nagy R., et al. A pilot study of buspirone in the treatment of social phobia. J Anxiety Disord. 5:1991;87-98.
122. Neal L.A., Shapland W., Fox C. An open trial of moclobemide in the treatment of post-traumatic stress disorder. Int Clin Psychopharmacol. 12:1997;231-237.
123. Oest L.G. Applied relaxation description of a coping technique and review of controlled studies . Behav Res Ther. 25:1987;397-409.
124. Oest L.G., Westling B.E., Hellstrom K. Applied relaxation, exposure in vivo and cognitive methods in the treatment of panic disorder with agoraphobia. Behav Res Ther. 31:(4):1993;383-394.
125. Otto MW, Pollack MH, Gould RA (1997): Access to empirically-supported treatment for panic disorder: costs, benefits and managed care. Paper presented at the Anxiety Disorders Association of America 17th National Conference, New Orleans, LA, March 20-23.
126. Otto M.W., Pollack M.H., Sachs G.S., Reiter S.R., Meltzer-Brody S., Rosembaum J.F. Discontinuation of benzodiazepine treatment Efficacy of cognitive-behavioral therapy for patients with panic disorder . Am J Psychiatry. 150:1993;1485-1490.
127. Pato M.T., Zohar-Kadouch R., Zohar J., Murphy D.L. Return of symptoms after discontinuation of clomipramine in patients with obsessive compulsive disorder. Am J Psychiatry. 145:1988;1521-1525.
128. Piggott T.A., Pato M.T., Bernstein S., Grover G.N., Hill J.L., Tolliver T.J., et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive compulsive disorder. Arch Gen Psychiatry. 47:1990;926-932.
129. Pohl R.B., Wolkow R.M., Clary C.M. Sertraline in the treatment of panic disorder A double-blind multicenter trial . Am J Psychiatry. 155:1998;1189-1195.
130. Pollack M.H., Otto M.W., Kaspi S.P., Hammerness P.G., Rosenbaum J.F. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry. 55:1994;200-205.
131. Priest R.G., Gimbrett R., Roberts M., Steinert J. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. Acta Psychiatr Scand. 91:(suppl 386):1995;40-43.
132. Rickels K., Case W.G., Downing R.W., Winokur A. Long-term diazepam therapy and clinical outcome. JAMA. 250:1983;767-771.
133. Rickels K., Downing R., Schweizer E., Hassman H. Anti-depressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry. 50:1993;884-895.
134. Rickels K., Weisman K., Norstad N., et al. Buspirone and diazepam in anxiety A controlled study . J Clin Psychiatry. 43:(12 Sec 2):1982;81-86.
135. Rocca P., Fonzo V., Scotta M., Zanalda E., Ravizza L., et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand. 95:1997;444-450.
136. Rothbaum B.O., Ninan P.T., Thomas L. Sertraline in the treatment of rape victims with posttraumatic stress disorder. J Trauma Stress. 9:1996;865-871.
137. Roy-Byrne P.P., Cowley D.S. Course and outcome in panic disorder A review of recent follow-up studies . Anxiety. 1:1995;151-160.
138. Schneier F.R., Franklin R., Saoud J.B., Campeas R., Fallon B.A., et al. Buspirone in social phobia. J Clin Psychopharmacol. 13:1993;251-256.
139. Schneier F.R., Martin L.Y., Leibowitz M.R., Gorman J.M., et al. Alcohol abuse in social phobia. J Anx Disord. 3:1989;15-23.
140. Scurfield R.M., Wong L.E., Zeerocah E.B. An evaluation of the impact of "helicopter ride therapy" for in-patient Vietnam vetrans with war-related PTSD. Milit Med. 157:1992;67-73.
141. Shalev A.Y., Bonne O., Eth S. Treatment of posttraumatic stress disorder A review . Psychosom Med. 58:1996;165-182.
142. Shapiro F. Eye movement desensitization A new treatment for post-traumatic stress disorder . J Behav Ther Exper Psychiatry. 20:1989;211-217.
143. Shear M.K., Beidel D.C. Psychotherapy in the overall management strategy for social anxiety disorder. J Clin Psychiatry. 59:(suppl 17):1998;39-44.
144. Shear M.K., Brown T.A., Barlow D.H., Money R., Sholomskas D.E., Woods S.W., et al. Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 154:1997;1571-1575.
145. Sherman J.J. Effects of psychotherapeutic treatments for PTSD A meta-analysis of controlled clinical trials . J Trau Stress. 11:1998;413-435.
146. Shestatsky M., Greenberg D., Lerer B. A controlled trial of phenelzine in post trumatic stress disorder. Psych Res. 24:1988;149-155.
147. Silver S.M., Brooks A., Obenchain J. Treatment of Vietnam veterans with PTSD A comparison of eye movement desensitization and reprocessing, biofeedback, and relaxation training . J Trauma Stress. 8:1995;337-342.
148. Smith DE (1988, October): Discontinuation methods for detoxification. Presented at "Benzodiazepines: Therapeutic, Biologic and Psychosocial Issues" meeting, Boston.
149. Solomon S.D., Gerrity E.T., Muff A.M. Efficacy of treatment for post-traumatic stress disorder. An empirical review. JAMA. 268:1992;633-688.
150. Spiegel D.A., Bruce T.J., Gregg S.F., Nuzzarello A. Does cognitive behavior therapy assist slow-taper alprazolam discontinuation in panic disorder? Am J Psychiatry. 151:1994;876-881.
151. Steiner M (1995, May): Long-term treatment and prevention of relapse in OCD with paroxetine. Presented at the annual meeting of the American Psychiatric Association, Miami.
152. Stein M.B., Chartier M.J., Hazen A.L., Kroft C.D., Chale R.A., Cote D., et al. Paroxetine in the treatment of generalized social phobia Open-label treatment and double-blind placebo-controlled discontinuation . J Clin Psychopharmacol. 16:1996;218-222.
153. Stein M.B., Liebowitz M.R., Lydiard R.B., Pitts C.D., Bushnell W., Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder) A randomized controlled trial . JAMA. 280:1998;708-713.
154. Sussman N. Treatment of anxiety with buspirone. Psychiatr Ann. 17:1987;114-120.
155. Sutherland S.M., Davidson J.R. Pharmacotherapy for post-traumatic stress disorder. Psychiatr Clin North Am. 17:1994;409-423.
156. Sutherland S.M., Tupler L.A., Colket J.T., Davidson J.R.T. A 2-year follow-up of social phobia. Status after a brief medication trial. J Nerv Ment Disord. 184:1996;731-738.
157. Taylor S. Meta-analysis of cognitive-behavioral treatments for social phobia. J Behav Ther Exp Psychiatry. 27:1996;1-9.
158. Taylor S., Woody S., Koch W.J., McLean P., Paterson R.J., Anderson K.W. Cognitive restructuring in the treatment of social phobia. Behav Modif. 21:1997;487-511.
159. Telch M.J., Lucas J.A., Schmidt N.B., Hanna H.H., Jaimez T.L., Lucas R.A. Group cognitive-behavioral treatment of panic disorder. Behav Res Ther. 31:1993;279-287.
160. Turner S.M., Beidel D.C., Cooley M.R., Woody S.R., Messer S.C. A multicomponent behavioral treatment for social phobia Social effectiveness therapy . Behav Res Ther. 32:1994;381-390.
161. Uhlenhuth E.H., Alexander P.E., Dempsey G.M., Jones W., Coleman B.S., Swiontek A.M. Medication side effects in anxious patients Negative placebo responses? J Affective Disord. 47:(1-3):1998;183-190.
162. Van Ameringen M., Mancini C., Streiner D.L. Fluoxetine efficacy in social phobia. J Clin Psychiatry. 54:1993;27-32.
163. Van Ameringen M., Mancini C., Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affective Disord. 39:1996;115-121.
164. Van Ameringen M.V., Mancini C., Oakman J.M. Nefazodone in social phobia. J Clin Psychiatry. 60:1999;96-100.
165. Van Balkom A.J., Bakker A., Spinhoven P., Blaauw B.M., Smeenk S., Ruesink B. A Meta-analysis of the treatment of panic disorder with or without agoraphobia A comparison of psychopharmacological, cognitive-behavioral, and combination treatments . J Nerv Ment Disord. 185:1997;510-516.
166. Van der Kilk B.A., Dreyfuss D., Michaels M., Shera D., Berkowitz R., Fisler R., et al. Fluoxetine in post traumatic stress disorder. J Clin Psychiatry. 55:1994;517-522.
167. Van Vliet M., Den Boer J.A., Westenberg H.G.M. Psychopharmacological treatment of social phobia Clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor . Eur Psychopharmacol. 2:1992;21-29.
168. Van Vliet M., Den Boer J.A., Westenberg H.G. Psychopharmacological treatment of social phobia A double-blind, placebo-controlled study with fluvoxamine . Psychopharmacol (Berlin). 115:1994;128-134.
169. Van Vliet I.M., Den Boer J.A., Westenberg H.G.M., Pian K.L.H. Clinical effects of buspirone in social phobia A double-blind, placebo-controlled study . J Clin Psychiatry. 58:1997;164-168.
170. Vaughan K., Wiese M., Gold R., Tarrier N. Eye-movement desensitiation. Symptom change in post-traumatic stress disorder. Br J Psychiatry. 164:1994;533-541.
171. Versiani M., Amerin R., Montgomery S.A. Social phobia Long-term treatment outcome and prediction of response-a moclobemide study . Intern Clin Psychopharmacol. 12:1997;239-254.
172. Versiani M., Nardi A.E., Mundim F.D., Alves A.B., Leibowitz M.R., Amrein R. Pharmacotherapy of social phobia A controlled study with moclobemide and phenelzine . Br J Psychiatry. 161:1992;353-360.
173. Welkowitz L.A., Papp L.A., Cloitre M. Cognitive behavior therapy for panic disorder delivered by psycho-pharmacologically oriented clinicians. J Nerv Ment Disord. 179:1991;473-477.
174. Wlazlo Z., Schroeder-Hartwig K., Hand I., Kaiser G., Munchau N. Exposure in vivo vs social skills training for social phobia Long-term outcome and differential effects . Behav Res Ther. 28:1990;181-193.
175. Zitrin C.M., Klein D.F., Woerner M.G. Behavior therapy, supportive spychotherapy, imipramine, and phobias. Arch Gen Psychiatry. 35:1978;307-316.
176. Zohar J., Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry. 169:(4):1996;468-474.